FMP
Plus Therapeutics, Inc.
PSTV
NASDAQ
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
1.09 USD
0.1 (9.17%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Marc H. Hedrick M.B.A., M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Au...
CIK
0001095981
ISIN
US72941H5090
CUSIP
72941H400
Address
4200 Marathon Boulevard
Phone
737 255 7194
Country
US
Employee
20
IPO Date
Jul 11, 2001
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
PSTV Financial Summary
CIK
0001095981
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
72941H400
ISIN
US72941H5090
Country
US
Price
1.09
Beta
0.69
Volume Avg.
91.55k
Market Cap
6.43M
Shares
-
52-Week
0.93-2.67
DCF
5.83
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.46
P/B
-
Website
https://www.plustherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PSTV News
It looks like there's no news available.
